Cargando…
Cardiovascular disease (CVD) risk assessment of HIV medication regimens using hematopoietic CD34+ progenitor cells
BACKGROUND: To determine the effects of integrase inhibitor (INSTI) in comparison with non-INSTI-based regimens such as non-nucleoside reverse transcriptase inhibitors (NNRTIs)-based regimens on cardiovascular disease (CVD) risk in HIV+ patients without overt history of CVD or diabetes, with normal...
Autores principales: | Elzarki, Adrian Farid, Nandula, Seshagiri Rao, Awal, Hassan, Simon, Gary L., Sen, Sabyasachi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8900400/ https://www.ncbi.nlm.nih.gov/pubmed/35255964 http://dx.doi.org/10.1186/s13287-022-02775-6 |
Ejemplares similares
-
Role of Canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes
por: Nandula, Seshagiri Rao, et al.
Publicado: (2021) -
Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial
por: Awal, Hassan B., et al.
Publicado: (2020) -
Comparison Between Linagliptin and Canagliflozin Effect on Inflammatory Markers, CD34+ Cell Gene Expression and Urine Exosomes in Type 2 Diabetes Subjects
por: Nandula, Seshagiri R, et al.
Publicado: (2021) -
Transplantation of Apoptosis‐Resistant Endothelial Progenitor Cells Improves Renal Function in Diabetic Kidney Disease
por: Kundu, Nabanita, et al.
Publicado: (2021) -
SUN-578 Role of Linagliptin on CD34+ Endothelial Progenitor Cells and Arterial Stiffness in Renal Function Impaired Type 2 Diabetes Subjects
por: Awal, Hassan, et al.
Publicado: (2020)